EUVIMEDEUVIMED entdecken
Open Access

Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections

Angelique E Boutzoukas, Natalie Mackow, Abhigya Giri, Lauren Komarow, Carol Hill, Liang Chen, Yohei Doi iD, Michael J Satlin, Cesar Arias, Minggui Wang iD, Laura Mora Moreo, Erica Herc und 6 weitere

Journal of Antimicrobial Chemotherapy · 04.11.2024 · 79 (11) · 2916-2922

DOI: 10.1093/jac/dkae306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.09.2024. Verfasst von Angelique E Boutzoukas und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Duke University, Durham, NC, USA. Hauptthemen laut MEDLINE: Enterobacteriaceae Infections, Community-Acquired Infections, Carbapenem-Resistant Enterobacteriaceae, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes for Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI).

Methods

Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI.

Results

Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P < 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P < 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%–64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P < 0.001].

Conclusion

We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterobacteriaceae InfectionsCommunity-Acquired InfectionsCarbapenem-Resistant EnterobacteriaceaeCOVID-19HumansMaleMiddle AgedFemaleAgedAdultProspective StudiesCross InfectionBacteremiaAnti-Bacterial AgentsSARS-CoV-2

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Duke University, Durham, NC, USA.
  • Duke Clinical Research Institute, Duke University, Durham, NC, USA.
  • Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.
  • The Biostatistics Center, George Washington University, Rockville, MD, USA.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine, Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
  • Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

ORCID-Profile: Yohei Doi, Minggui Wang, Gregory Weston, Robin Patel, David van Duin

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes for Allergy and Infectious Diseases
  • NIH
  • National Institutes of Health

Zitieren

APA

Boutzoukas, A. E., Mackow, N., Giri, A., Komarow, L., Hill, C., Chen, L., Doi, Y., Satlin, M. J., Arias, C., Wang, M., Mora Moreo, L., Herc, E., Cober, E., Weston, G., Patel, R., Bonomo, R. A., Fowler, V., & van Duin, D. (2024). Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections. Journal of Antimicrobial Chemotherapy, 79(11), 2916-2922. https://doi.org/10.1093/jac/dkae306

Vancouver

Boutzoukas AE, Mackow N, Giri A, Komarow L, Hill C, Chen L, et al. Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections. Journal of Antimicrobial Chemotherapy. 2024;79(11):2916-2922. doi:10.1093/jac/dkae306

BibTeX
@article{Boutzoukas2024,
  author = {Boutzoukas, Angelique E and Mackow, Natalie and Giri, Abhigya and Komarow, Lauren and Hill, Carol and Chen, Liang and Doi, Yohei and Satlin, Michael J and Arias, Cesar and Wang, Minggui and Mora Moreo, Laura and Herc, Erica and Cober, Eric and Weston, Gregory and Patel, Robin and Bonomo, Robert A and Fowler, Vance and van Duin, David},
  title = {Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {2916--2922},
  doi = {10.1093/jac/dkae306}
}
Kostenlos starten →